Amar­in's Vas­cepa reigns supreme in fish oil bat­tle, as As­traZeneca's ri­val fiz­zles

As­traZeneca’s com­pet­i­tive threat to Amarin’s mighty Vas­cepa in pa­tients with car­dio­vas­cu­lar risk has wilt­ed.

On Mon­day, the British drug­mak­er said it was aban­don­ing a large …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER